Key Takeaways LLY's orforglipron outperformed Rybelsus in reducing A1C and body weight at 52 weeks.In ACHIEVE-3, orforglipron cut A1C by up to 2.2% at 52 weeks vs. 1.4% with Rybelsus.Orforglipron also improved cholesterol, blood pressure and triglycerides with good tolerability.Eli Lilly (LLY) announced positive top-line data from a late-stage head-to-head study evaluating its once-daily small molecule (non-peptide) oral GLP-1 receptor agonist, orforglipron, compared to Novo Nordisk’s (NVO) Rybelsus (oral s ...